113 related articles for article (PubMed ID: 20951488)
21. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
22. Spurious hyperphosphatemia in a dog with chronic lymphocytic leukemia and an IgM monoclonal gammopathy.
Kristensen AT; Klausner JS; Weiss DJ; Schultz RD; Bell FW
Vet Clin Pathol; 1991; 20(2):45-48. PubMed ID: 12673545
[TBL] [Abstract][Full Text] [Related]
23. [Management of hyperphosphatemia in patients with chronic kidney disease].
Savica V; Santoro D; Monardo P; Mallamace A; Bellinghieri G
G Ital Nefrol; 2009; 26 Suppl 46():58-61. PubMed ID: 19644820
[TBL] [Abstract][Full Text] [Related]
24. Spuriously elevated inorganic phosphate level in a multiple myeloma patient.
Barutçuoglu B; Parildar Z; Mutaf I; Habif S; Bayindir O
Clin Lab Haematol; 2003 Aug; 25(4):271-4. PubMed ID: 12890170
[TBL] [Abstract][Full Text] [Related]
25. Sural nerve T cells in demyelinating polyneuropathy associated with monoclonal gammopathy.
Eurelings M; Notermans NC; Wokke JH; Bosboom WM; Van den Berg LH
Acta Neuropathol; 2002 Feb; 103(2):107-14. PubMed ID: 11810175
[TBL] [Abstract][Full Text] [Related]
26. Analysis of paraprotein transport into the saliva by using anti-idiotype antibodies.
Kubagawa H; Bertoli LF; Barton JC; Koopman WJ; Mestecky J; Cooper MD
J Immunol; 1987 Jan; 138(2):435-9. PubMed ID: 3794339
[TBL] [Abstract][Full Text] [Related]
27. Spurious hyperphosphataemia caused by an IgA paraprotein: a topic revisited.
Sinclair D; Smith H; Woodhead P
Ann Clin Biochem; 2004 Mar; 41(Pt 2):119-24. PubMed ID: 15025801
[TBL] [Abstract][Full Text] [Related]
28. Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin.
Mandry JM; Posner MR; Tucci JR; Eil C
Cancer; 1991 Sep; 68(5):1092-4. PubMed ID: 1913479
[TBL] [Abstract][Full Text] [Related]
29. Spurious Hyperphosphatemia in a Patient with Chronic Kidney Disease - a Rare Case of Alteplase Contamination.
Khan ZUN; Ahmed S; Siddiqui A; Siddiqui I
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623682
[TBL] [Abstract][Full Text] [Related]
30. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
31. Hyperphosphatemia in multiple myeloma.
Oren S; Feldman A; Turkot S; Lugassy G
Ann Hematol; 1994 Jul; 69(1):41-3. PubMed ID: 8061106
[TBL] [Abstract][Full Text] [Related]
32. [Isotypic characterization of IgA paraproteins: association with other clinical and analytic data].
González González JB; García Delgado R; Cámara Sáez E; Ortiz Maslloréns F
Rev Clin Esp; 1996 Aug; 196(8):529-35. PubMed ID: 8984539
[TBL] [Abstract][Full Text] [Related]
33. Spurious hyperphosphatemia in patients with dysglobulinemia.
Weinberg J; Adler AJ
Miner Electrolyte Metab; 1989; 15(4):185-6. PubMed ID: 2761487
[TBL] [Abstract][Full Text] [Related]
34. [Sézary syndrome associated with hepatocellular carcinoma and monoclonal gammopathy--a case report].
Shimamura R; Kaneko T; Morioka E; Shibuya T; Ishibashi H; Niho Y
Rinsho Ketsueki; 1989 Jul; 30(7):1067-73. PubMed ID: 2554013
[TBL] [Abstract][Full Text] [Related]
35. [Management of monoclonal gammopathy].
Huijgens PC; Zweegman S
Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1401-2. PubMed ID: 12174432
[TBL] [Abstract][Full Text] [Related]
36. Phosphate is a uremic toxin.
Burke SK
J Ren Nutr; 2008 Jan; 18(1):27-32. PubMed ID: 18089440
[TBL] [Abstract][Full Text] [Related]
37. Interferences in the measurement of circulating phosphate: a literature review.
Molinaris V; Bianchetti MG; Milani GP; Lava SAG; Bruna RD; Simonetti GD; Faré PB
Clin Chem Lab Med; 2020 Nov; 58(12):1971-1977. PubMed ID: 32549132
[TBL] [Abstract][Full Text] [Related]
38. Low prevalence of hyperphosphatemia independent of residual renal function in peritoneal dialysis patients.
Dong J; Wang H; Wang M
J Ren Nutr; 2007 Nov; 17(6):389-96. PubMed ID: 17971311
[TBL] [Abstract][Full Text] [Related]
39. Niacin and related compounds for treating hyperphosphatemia in dialysis patients.
Berns JS
Semin Dial; 2008; 21(3):203-5. PubMed ID: 18363600
[TBL] [Abstract][Full Text] [Related]
40. Spurious hyperphosphatemia in a case of multiple myeloma.
Chakraborty S; Sen S; Gupta D; Ghosh SS; Sawant P; Das M
Indian J Clin Biochem; 2014 Apr; 29(2):250-2. PubMed ID: 24757312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
